Trial Profile
A study of AVXS 101 in patients with spinal muscular atrophy type 1, 2, 3.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Aug 2021
Price :
$35
*
At a glance
- Drugs Onasemnogene-abeparvovec (Primary)
- Indications Spinal muscular atrophy
- Focus Therapeutic Use
- Acronyms REACH
- 03 Aug 2021 According to a Novartis media release, the U.S. Food and Drug Administration (FDA) has lifted partial clinical hold based on data from Novartis comprehensive nonclinical toxicology study in non-human primates (NHP) that addressed all issues identified, including questions of dorsal root ganglia (DRG) injury following IT administration.
- 03 Aug 2021 Status changed from suspended to recruiting, according to a Novartis media release.
- 30 Oct 2019 According to a Novartis media release, FDA has placed a partial hold on AVXS-101 intrathecal clinical trials for SMA patients based on findings in a small pre-clinical animal study. This partial hold by the FDA does not impact marketed Zolgensma or AVXS-101 intravenous (IV) clinical trials. Novartis is working with FDA to determine next steps to release partial hold and resume dosing in the AVXS-101 intrathecal trials.